Journal article
Pi3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer
F Roncolato, K Lindemann, ML Willson, J Martyn, L Mileshkin
Cochrane Database of Systematic Reviews | WILEY | Published : 2019
Abstract
Background Endometrial cancer is one of the most common gynaecological cancers in developed countries. Treatment of advanced endometrial cancer usually involves radiotherapy, chemotherapy, endocrine therapy or a combination of these. However, survival outcomes are poor in advanced or metastatic disease. Better systemic treatment options are needed to improve survival and safety outcomes for these women. The PI3K/AKT/mTOR pathway is a frequently altered signalling pathway in endometrial cancer. Single-arm studies have reported some encouraging results of the PI3K/AKT/mTOR inhibition in advanced or recurrent endometrial cancer. Objectives To assess the efficacy and safety of PI3K/AKT/mTOR inhi..
View full abstractGrants
Funding Acknowledgements
This project was supported by the National Institute for Health Research (NIHR), via Cochrane Infrastructure funding to the Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group. The views and opinions expressed herein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, National Health Service or the Department of Health, United Kingdom.